PI3K Inhibition Restores and Amplifies Response to Ruxolitinib in Patients with Myelofibrosis.

Ruxolitinib Versus Best Available Therapy for Polycythemia Vera Intolerant or Resistant to Hydroxycarbamide in a Randomized Trial.

Early intervention in myelofibrosis and impact on outcomes: A pooled analysis of the COMFORT-I and COMFORT-II studies.

Moving beyond ruxolitinib failure in myelofibrosis: evolving strategies for second line therapy.

The NUTRIENT Trial (NUTRitional Intervention among myEloproliferative Neoplasms): Feasibility Phase.

Symptomatic benefit of momelotinib in patients with myelofibrosis: Results from the SIMPLIFY phase III studies.

Momelotinib Long-Term Safety and Survival in Myelofibrosis: Integrated Analysis of Phase 3 Randomized-Controlled Trials.

Long-Term Hematologic Improvement in a Patient With Cytopenic Myelofibrosis Treated With Pacritinib.

Diastolic Blood Pressure and Cognitive Functioning: Differences by Systolic Blood Pressure Among US Adults.

Anemia in myelofibrosis: Current and emerging treatment options.